Inhibition of CD20 mRNA expression by ibrutinib correlates with reduced NF-κB activity. Inhibition of CD20 mRNA expression by ibrutinib correlates with.

Slides:

Advertisements

Similar presentations

Dominant IL-21 expression in TFH cells correlate with B cell pathology in HIV-infected LNs. Dominant IL-21 expression in TFH cells correlate with B cell.

Advertisements

Supplemental Digital Content 2 – Figure 2

Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection by Shokrollah Elahi, Toshiro Niki, Mitsuomi Hirashima,

Interleukin (IL)-1β-producing cells in peripheral blood mononuclear cells (PBMCs). Interleukin (IL)-1β-producing cells in peripheral blood mononuclear.

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

Omalizumab treatment downregulates dendritic cell FcεRI expression

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

Figure 2 Alemtuzumab-induced changes in the dendritic cell compartment

Meta-Analysis of Hepatitis C Virus Vaccine Efficacy in Chimpanzees Indicates an Importance for Structural Proteins Harel Dahari, Stephen M. Feinstone,

Comparison of relative activity of Adjuplex and other commonly used adjuvants. Comparison of relative activity of Adjuplex and other commonly used adjuvants.

Figure 5 Alemtuzumab-induced changes in the innate lymphoid cell (ILC) compartment Alemtuzumab-induced changes in the innate lymphoid cell (ILC) compartment.

Alterations related to androgen signaling.

IL-10 upregulates IgG4 production by CD27+ B cells.

Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS by Takeshi Sugio, Kohta Miyawaki, Koji Kato, Kensuke Sasaki, Kyohei Yamada,

Recruitment of T cells to the lung in response to antigen challenge

Non-typeable Haemophilus influenzae (NTHi)-stimulated cytokine production. Non-typeable Haemophilus influenzae (NTHi)-stimulated cytokine production. Peripheral.

Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease by Jennifer S. Whangbo, Haesook.

Schematic depiction of CTC processing methods.

Figure 2 Peripheral blood lymphocyte subset counts during dimethyl fumarate treatment(A) Lymphocyte subsets were obtained at baseline (n = 21) and at month.

Figure 1 BG-12 treatment reduced total circulating B cells and had variable effects on memory B cells BG-12 treatment reduced total circulating B cells.

MRNA expression levels of the gene encoding CAR in isolated human islets from control donors, cultured for prolonged time (n=2). mRNA expression levels.

Figure 3 Flu immunization–induced changes in the proportions and absolute numbers of RORγt-expressing CD4+ and CD8+ T cells Flu immunization–induced changes.

Figure 2 Effect of DMF therapy on the T helper cell repertoire and cytokine production Effect of DMF therapy on the T helper cell repertoire and cytokine.

Relationship between blood cell and plasma miRNA expression among published circulating cancer biomarkers. Relationship between blood cell and plasma miRNA.

Figure 3 Alemtuzumab-induced changes in monocytes

ABT-199 efficiently kills primary AML myeloblasts as a single agent.

Gene expression changes associated with response to combination CPI-444 and anti–PD-L1 treatment in MC38 tumors. Gene expression changes associated with.

Plots showing baseline correlation between the modified Medical Research Council (mMRC) dyspnoea scale, Baseline Dyspnoea Index (BDI), COPD Assessment.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Leukemic blasts express a “hypoxia signature

PD-L1 expression correlates with T-cell markers and an IFN response signature in human melanomas. PD-L1 expression correlates with T-cell markers and an.

Colony-forming capacity of CD34+ cells with and without CLL-1 expression. Colony-forming capacity of CD34+ cells with and without CLL-1 expression. CD34+

Expression of genes related to inflammasome activation in peripheral blood mononuclear cell (PBMC) and bronchoalveolar lavage (BAL) macrophages. Expression.

Β-Cryptoxanthin at a concentration of 10 μmol/L decreases proliferation in HCT116 cells after 6 and 8 days of treatment. β-Cryptoxanthin at a concentration.

CNDT2.5 cells express mRNA for synaptophysin and neuron-specific enolase. CNDT2.5 cells express mRNA for synaptophysin and neuron-specific enolase. RT-PCR.

CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.

Pre- and post-vorinostat values of ER-related gene expression using the Oncotype DX 21-gene assay. Pre- and post-vorinostat values of ER-related gene expression.

Pre- and post-vorinostat values of proliferation-associated gene expression using the Oncotype DX 21-gene assay. Pre- and post-vorinostat values of proliferation-associated.

A, RT-PCR expression of matriptase-1 and matriptase-2 in a variety of 24 human cell lines. A, RT-PCR expression of matriptase-1 and matriptase-2 in a variety.

SAF-1 expression in clinical breast cancer tissues.

MRNA expression IL-1α, IL-1β, IL-1Ra, IL-1RtI, ER α, ER β, and PR was analyzed by RT-PCR as described in “Materials and Methods.” Representative gel electrographies.

Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.

A, change in Ki-67 expression (percent of cells staining positive) over the course of the intervention. A, change in Ki-67 expression (percent of cells.

Mir-128 reduction in breast cancer tissues correlates chemotherapy resistance and poor patient survival. Mir-128 reduction in breast cancer tissues correlates.

Detection of PSA-mRNA by single (first panel, 710 bp) and nested (second panel, 455 bp) RT-PCR. Detection of PSA-mRNA by single (first panel, 710 bp) and.

Dysregulated NF-κB activation in Il1r8+/+/lpr and Il1r8−/−/lpr mice.

Immunologic and pharmacokinetic studies.

PAP- and PA2024-specific CTLs at week 0 (prior to sipuleucel-T infusion) and at weeks 6 and 26 post–sipuleucel-T treatment. PAP- and PA2024-specific CTLs.

Nested RT-PCR of Mammaglobin and CK19 mRNA in plasma and circulating cells of controls (C) and patients (T) with breast cancer. Nested RT-PCR of Mammaglobin.

Gene expression levels of ESR1 (A), ERBB2 (B), MiK67(C), and PCNA (D) in pre- and postneoadjuvant chemotherapy samples (n = 21). Gene expression levels.

Bortezomib induces an NRF2 signature and NRF2 protein in tumor cells from leukemic MCL. Gene sets regulated by bortezomib (Supplementary Tables S3 and.

Coexpression of other immune genes with ImSig core signatures.

Reduced klotho expression in pancreatic cancer.

Activation status of CD8+ T cells.

Intratumoral changes in critical lymphocyte populations and numbers after NKTR-214 treatment. Intratumoral changes in critical lymphocyte populations and.

Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex treatment. Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex.

Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Expression.

Specific reaction with MIB1, M30, and CD31 monoclonal antibodies in primary human cervical carcinoma before (A, C, and E) and after (B, D, and F) Tam treatment.

ICOS+ and activated CD4+ T cells are dominant, tumour tissue-specific T cell populations in both mismatch repair-deficient and repair-proficient colorectal.

Impact of IFNγ in B16 melanoma metastasis.

CpG oligodeoxynucleotide (CpG ODN)–induced activation of different types of primary malignant B cells. CpG oligodeoxynucleotide (CpG ODN)–induced activation.

Reduced expression of the tumor suppressor PTEN occurs in tumors with both squamous cell and adenocarcinoma histology. Reduced expression of the tumor.

Ibrutinib decreases ofatumumab-mediated complement-dependent cytotoxicity. Ibrutinib decreases ofatumumab-mediated complement-dependent cytotoxicity. A,

A and B, linearity of the preamplification step shown by a similar expression pattern of ERα mRNA in four breast tumor samples pre– and post–linear amplification.

LDL cholesterol inhibits Vγ9Vδ2 T-cell activation and cytokine production. LDL cholesterol inhibits Vγ9Vδ2 T-cell activation and cytokine production. Preexpanded.

Expression of chemokine receptors in A-498 cell line.

Correlations between APOBEC expression and immune cell markers across 22 cancer types. Correlations between APOBEC expression and immune cell markers across.

In situ expression of signature genes in the Th1, Th2, Th17, and Treg pathways. In situ expression of signature genes in the Th1, Th2, Th17, and Treg pathways.

Highly metastatic PDAC cells have a unique gene signature, which is not preserved in metastases but predicts poor patient outcome. Highly metastatic PDAC.

Construction of TME signatures and functional annotation.

Presentation transcript:

Inhibition of CD20 mRNA expression by ibrutinib correlates with reduced NF-κB activity. Inhibition of CD20 mRNA expression by ibrutinib correlates with reduced NF-κB activity. A, expression of CD20 mRNA was quantified by RT-PCR in CD19+ PBMCs on day 2 (n = 8) and after 1 month (day 28, n = 12) on ibrutinib. The percent change on treatment compared with baseline is shown. B, correlation between CD20 mRNA (MS4A1 gene) expression and CD20 cell surface expression on CLL cells on day 28, n = 8. C, correlation between NF-κB signature score and CD20 gene expression. LN core biopsies (day 2, n = 11) are shown as triangles, whereas day 28 peripheral blood samples are represented as circles (n = 12). Panels B and C are shown on a log2 scale. P values for all comparisons were calculated using the matched-pairs Wilcoxon signed-rank test. Correlations were determined using the Pearson test. The whiskers on all box plots depict the range (minimum and maximum values). Martin Skarzynski et al. Clin Cancer Res 2016;22:86-95 ©2016 by American Association for Cancer Research